N-Methyl-N-(propan-2-yl)prop-2-enamide | 87322-78-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Methyl-N-(propan-2-yl)prop-2-enamide
• 英文别名: N-methyl-N-propan-2-ylprop-2-enamide
• CAS: 87322-78-9
• 化学式: C₇H₁₃NO
• 分子量: 127.18
• InChiKey: COYVWKMZTCAFHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  N-异丙基甲胺 、 丙烯酰氯 生成 N-Methyl-N-(propan-2-yl)prop-2-enamide
  参考文献：
  名称：

  ITO, SEDZI;MIDZOGUTI, KEHNSAKU;SUDA, MASAO

  摘要：

  DOI：

文献信息

• ERK INHIBITORS AND USES THEREOF
  申请人：Celgene Avilomics Research, Inc.

  公开号：US20140228322A1

  公开（公告）日：2014-08-14

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用它们的方法。
• Mucosal formulation
  申请人：Boga Rameshbabu

  公开号：US20070264206A1

  公开（公告）日：2007-11-15

  A mucosal formulation for administration to mucosal membranes, such as in the mouth, nasal passage, stomach, vagina, etc., is disclosed. The mucosal formulation contains a lipid-pharmaceutical agent complex formed from phospholipids possessing a hydrophobic moiety that orients into a hydrophobic phase and a polar head moiety that orients towards the aqueous phase (i.e., “amphipathic” lipids). When placed in an aqueous medium (e.g., vaginal fluid), the phospholipids form liposomes or other small lipid vesicles (e.g., micelles) that may then be used to deliver pharmaceutical agents into a living organism.

  揭示了一种用于给粘膜膜的制剂，例如口腔、鼻腔、胃、阴道等。这种粘膜制剂包含从磷脂中形成的含有疏水部分的脂质-药物复合物，该疏水部分朝向疏水相，极性头部分朝向水相（即“两性”脂质）。当置于水性介质中（例如阴道液），磷脂形成脂质体或其他小的脂质囊泡（例如胶束），然后可用于将药物输送到活体内。
• Perivascular wraps
  申请人：Gravett M David

  公开号：US20080085855A1

  公开（公告）日：2008-04-10

  The present invention provides compositions, devices, and methods for maintaining or improving the integrity of body passageways following surgery, such as at a graft site, or injury. Delivery devices including one or more therapeutic agents and a mesh are described. Representative examples of therapeutic agents include microtubule stabilizing agents, anti-angiogenic factors, inhibitors of smooth muscle cell growth or proliferation, non-steroidal anti-inflammatory drugs, and other factors useful preventing and/or reducing a proliferative biological response that may obstruct or hinder the optimal functioning of the passageway or cavity.

  本发明提供了维持或改善手术后身体通道完整性的组合物、装置和方法，例如在移植部位或受伤处。描述了包括一个或多个治疗剂和网状物的输送装置。治疗剂的代表性例子包括微管稳定剂、抗血管生成因子、平滑肌细胞生长或增殖抑制剂、非甾体抗炎药和其他有用的因子，用于预防和/或减少可能阻碍或妨碍通道或腔体的最佳功能的增殖生物反应。
• Compositions and methods for coating medical implants
  申请人：Angiotech Pharmaceuticals, Inc.

  公开号：US20040043052A1

  公开（公告）日：2004-03-04

  Medical implants are provided which release an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, and/or platinum complex, thereby inhibiting or reducing the incidence of infection associated with the implant.

  提供释放蒽环素、氟嘧啶、叶酸拮抗剂、鬼臼毒素、喜树碱、羟基脲和/或铂配合物的医疗植入物，从而抑制或减少与植入物相关的感染的发生率。
• [EN] COSMECEUTICAL COMPOSITION<br/>[FR] COMPOSITION COSMÉCEUTIQUE
  申请人：TRIM EDICINE INC

  公开号：WO2021150383A1

  公开（公告）日：2021-07-29

  Cosmeceutical compositions for and methods of improving the appearance of skin and promoting hair growth are provided. Said compositions comprise at least one ROS-scavenging polymer gel, at least MG53, or a combination thereof. A novel boronate ester- based copolymer forms an aqueous hydrogel exhibiting lower viscosity at cooler temperatures and higher viscosity at higher temperatures is provided.

  提供了一种用于改善皮肤外观和促进头发生长的化妆品组合物和方法。所述组合物包括至少一种ROS清除聚合物凝胶，至少MG53，或其组合物。提供了一种新型的硼酸酯基共聚物形成水性水凝胶，在较低温度下具有较低的粘度，在较高温度下具有较高的粘度。